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Barrett’s oesophagus is a premalignant condition whose incidence is rising dramatically. Molecular markers are urgently needed to
identify Barrett’s patients at the highest risk of cancer progression. To this end, we have used a rapid molecular technique, restriction
site mutation (RSM), to detect low-frequency mutations in the p53 tumour suppressor gene in premalignant Barrett’s tissues of
cancer-free patients. In total, 38 endoscopically diagnosed Barrett’s patients with a range of histological stages of Barrett’s progression,
plus four control patients without Barrett’s oesophagus, were analysed for early p53 mutations. Tissue samples taken from these
patients (93 samples in total) were analysed for the presence of low-frequency p53 mutations at hotspot codons: 175, 213, 248, 249,
282. In total, 13 of the 38 Barrett’s patients were shown to possess a p53 mutation in at least one sample (no mutations in the four
control patients). Although no statistically significant associations were found, p53 mutations reflected histological progression in
Barrett’s patients with p53 mutations found in 30% of metaplasia patients (P¼0.4) and low-grade dysplasia patients (P¼0.33) and
45% of high-grade dysplasia patients (P¼0.15). Detected p53 mutations were mainly GC to AT transitions at CpG sites.
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Barrett’s metaplasia is a precursor of adenocarcinoma of the
oesophagus, the incidence of which is rising dramatically in
Western countries (Watson, 2000). Metaplastic Barrett’s epithe-
lium may progress through low-grade dysplasia (LGD) and high-
grade dysplasia (HGD) to cancer. Patients with a metaplastic
Barrett’s segment have a 30–125-fold greater risk of adenocarci-
noma than non-Barrett’s patients (Cameron et al, 1985). The
driving force behind cancer development in Barrett’s tissues is
thought to be oesophageal inflammation induced by chronic reflux
of stomach acid and duodenal fluid (Chen and Yang, 2001).
Inflamed tissues are known to be cancer prone (Ambs et al, 1999),
partly because of their increased cell proliferation rates (Sjoqvist
et al, 1999). The reactive oxygen species (ROS) produced during
such inflammation (e.g. superoxide, hydrogen peroxide, nitric
oxide) are complete carcinogens in their own right (Cerutti and
Trump, 1991; Dreher and Junod, 1996). However, coincident
exposure of inflamed tissues to mutagens (possibly bile acids in
the case of Barrett’s patients) can exacerbate carcinogenesis.
Progression of Barrett’s metaplasia to adenocarcinoma is
accompanied by a range of genetic alterations (Fitzgerald and
Triadafilopoulos, 1998; Jankowski et al, 1999; Jenkins et al, 2002),
including loss of p53 tumour suppressor function. The most
common mechanism of p53 loss is through the accumulation of
mutations at one of eight hotspot codons (Hainaut and Hollstein,
2000). p53 loss is significant in cancer development because of the
role that p53 plays in maintaining genomic stability. It is well
known that p53 loss leads to increased spontaneous mutation rates
(Havre et al, 1995), chromosome instability (Bouffler et al, 1995)
and aneuploidy (Fukasawa et al, 1996). These latter two events are
characteristic of Barrett’s progression (Jenkins et al, 2002). Indeed,
it has been shown that p53 mutation precedes (and perhaps leads
to) aneuploidy in Barrett’s tissues (Neshat et al, 1994; Prevo et al,
1999).
The role of p53 mutation in Barrett’s tumour progression has
been studied previously, with p53 mutations being detected in
Barrett’s tumours and in adjacent dysplastic tissue. However, p53
mutation has been poorly studied in premalignant Barrett’s tissues,
especially in cancer-free patients (Prevo et al, 1999). This lack
of p53 mutation data has led to controversy with respect to the
timing of p53 mutation in Barrett’s progression (Fitzgerald and
Triadafilopoulos, 1998). Table 1 contains a list of published p53
mutation data for Barrett’s tissues. Most of these data come from
tumour samples, with some data available for adjacent premalig-
nant Barrett’s tissue (mostly dysplasia). The data in Table 1 are
solely derived from molecular studies on p53 gene mutations in
Barrett’s tissue and do not include the inference of p53 mutations
by immunohistochemistry (IHC). Using IHC as a surrogate for p53
mutation has been widely described as unsatisfactory (Hamelin
et al, 1994; Schneider et al, 1996; Gleeson et al, 1998). From Table 1,
it is evident that while some authors claim that p53 mutations are
detectable in metaplastic tissue (Casson et al, 1991) or low-grade
dysplastic tissue (Gleeson et al, 1998; Bian et al, 2001), most
authors only detect mutations in tissues containing high-grade
dysplasia or cancer (Hamelin et al, 1994; Audrezet et al, 1996).
This discrepancy is probably because of the methodological
shortcomings of these studies (Minamoto and Ronai, 2001). It is
well known that there is an inverse correlation between the
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with which it is detected (Minamoto and Ronai, 2001). In order to
detect early p53 mutations in premalignant tissue of cancer-free
patients, methodologies must enrich for mutated sequences at the
expense of the more abundant nonmutated sequences (Minamoto
and Ronai, 2001).
In this paper, we present a relatively simple molecular technique
called restriction site mutation (RSM) (Jenkins et al, 1999,
2001a,b) and assess its ability to detect early p53 mutations in
premalignant Barrett’s tissues from patients without clinically
detectable adenocarcinoma. This approach has previously been
employed in detecting p53 mutations in ulcerative colitis patients
(Ambs et al, 1999) and gastritis patients (our laboratory,
unpublished results). Restiction site mutation couples the se-
quence specificity of restriction enzymes to the amplification
power of PCR in order to ‘fish out’ low-frequency mutated p53
sequences from among excess nonmutated sequences. The RSM
technique exploits the fact that five of the eight main p53 mutation
hotspots detected in cancers, that is, codons 175, 213, 248, 249, 282,
contain restriction enzyme sites, thus allowing RSM to detect low-
frequency mutations at these codons. In previous studies, we have
shown that using spiked DNA samples, mutated hotspots are
detectable even when in the presence of a 10000-fold excess of
nonmutated sequences (Jenkins et al, 2001a,b).
The aim of this prospective study was to (i) assess whether RSM
could detect early p53 mutations in premalignant Barrett’s tissue,
(ii) correlate the presence of any early p53 mutations with
histological grade and (iii) assess the value of early p53 mutation
as a biomarker for cancer risk in Barrett’s patients.
MATERIALS AND METHODS
Collection of biopsies from Barrett’s patients
Biopsies were obtained from consenting Barrett’s patients during
routine endoscopy clinics (ethical approval obtained). Biopsies for
DNA analysis were obtained from Barrett’s mucosa immediately
adjacent to the biopsy sites for mucosa sent for histopathological
analysis. These biopsies were obtained using large forceps and the
whole biopsy (B10mg) was required for DNA extraction in order
to provide sufficient DNA (B30mg) for mutation analysis.
Histopathological staging of the Barrett’s patients was determined
by the consensus view of a panel of three pathologists (APG, NT,
VS). Barrett’s patients were graded as dysplastic even if this was
evident in only one of the biopsy specimens examined, as
previously described (Prevo et al, 1999). A total of 38 patients
with a range of histopathological stages of Barrett’s oesophagus
were recruited over a 12-month period (follow up: 9–20 months).
Biopsies in four patients contained only squamous epithelium, 13
had Barrett’s metaplasia without dysplasia, 14 had LGD and seven
had HGD. In addition, paraffin-embedded archival tissue sections
from surgically resected tissues were used to increase the numbers
of HGD patients from seven to 11. From these 42 patients, 93 tissue
samples were collected (average two biopsies per patient). The
seven biopsies obtained from the four patients with squamous
epithelium were considered as an internal control group in this
study. Biopsies were immediately stored on ice until DNA
extraction could be performed.
DNA extraction
Biopsies were minced on a clean microscope slide using a clean
scalpel blade. The minced tissues were then subjected to DNA
extraction using a high-salt approach (Stratagene, Cambridge,
UK). In the case of the paraffin-embedded tissue sections, the
tissue was first scraped off five 5mm slides and incubated with
500ml of xylene to dissolve the paraffin. The tissue was
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ssubsequently pelleted by centrifugation and washed with 70%
ethanol before proceeding with the DNA extraction (as above).
After DNA extraction, the quantity and purity of the DNA was
assessed by spectrophotometry at 260/280nm and by 1% agarose
electrophoresis. The DNA concentration was adjusted to
100ngml
 1 and the DNA stored at  201C.
Restriction site mutation analysis
The DNA extracted from oesophageal tissue samples was analysed
for mutations occurring in five restriction enzyme sites of the
human p53 gene. These restriction sites covered the hotspot
codons 175, 213, 248, 249 and 282. A total of 465 RSM analyses
were performed with the Barrett’s samples (93 tissue samples
analysed at each of five restriction enzyme sites). Table 2 contains
details of the restriction enzymes used and the PCR conditions
employed to amplify the mutant sequences. A previous study by
ourselves has shown that using spiked tumour DNA bearing a p53
mutation, the RSM method can detect such mutations even when
present among a 10000-fold excess of nonmutated DNA (Jenkins
et al, 2001a,b).
Initial digestion DNA (1.5mg containing 4 10
5 copies of the p53
gene) was subject to restriction digestion with 10–20U of the
particular enzyme under test. In the case of the paraffin-embedded
tissue sections, the low yield of DNA meant that only 500ng of
DNA was included in the RSM analysis. The initial digestion was
performed in a volume of 20ml of magnesium-free Taq Polymerase
buffer (Promega Corporation, Southampton, UK) supplemented
with 1.5mM MgCl2. The digestion was performed at the optimum
temperature overnight (16h). The following morning, a further
10U of restriction enzyme was added for 1h, to ensure maximum
digestion of the nonmutated DNA.
Polymerase chain reaction amplification Following digestion, the
undigested (mutated) sequences were amplified by PCR using
primers (Table 2) flanking the restriction site under examination
(Cruachem, Glasgow, Scotland). The PCR amplification was per-
formed in 1 magnesium-free Taq polymerase buffer (Promega
Corp.), along with 1.5mM MgCl2, 100mM dNTPs (Promega Corp.),
10pmol of each primer (Cruachem), 20ml of digested DNA and
2.5U of Taq polymerase (Promega Corp.), in a final volume of
50ml. Positive (uncut DNA) and negative (no DNA) controls for
the PCR step were also included.
Final digestion After amplification, the PCR product (16ml) was
further digested overnight in a final volume of 20ml, with 10U of
the restriction enzyme under test (this time in enzyme-specific
digestion buffer) to remove any wild-type sequences that may have
escaped the initial digestion.
Electrophoresis The RSM products were then visualised on 5%
polyacrylamide gels (Biorad, Hemel Hempstead, UK) and post-
stained with silver. Restriction enzyme-resistant RSM products
were detected on the gels as undigested bands of the correct size,
by comparison to the PCR-positive control (see Figure 1).
As a control for inefficient enzyme digestion, all RSM
experiments included commercially obtained human DNA (Pro-
mega Corp.) deemed to be free from mutations. Complete
digestion of this control was a prerequisite for accepting mutations
in accompanying samples. Fisher’s exact test was employed to
compare the frequency of p53 mutations between histologies.
Sequencing
Mutations detected in this study by their resistance to restriction
enzyme digestion were all confirmed by DNA sequencing. Enzyme-
resistant products were reamplified by PCR using 1ml of the final
RSM product (amplification for 10–12 cycles using appropriate
thermal profiles). The reamplified samples were electrophoresed
on 5% polyacrylamide gels and stained with silver to ensure that
discrete bands were produced. These PCR products were then
sequenced using a cycle sequencing kit (Beckman Coulter, High
Wycombe, UK) and run on an automated DNA sequencer
Table 2 Details of the restriction enzymes employed in this study to detect p53 mutations at key tumour hotspot codons; also included are the PCR
primer sequences for each hotspot codon and the amplification conditions
p53 exon
Restriction
enzymes
Digestion
temperature (1C)
Forward
primer
Reverse
primer
PCR
product
size (bp)
Anneal
temperature
(1C)
Cycle
number
Exon 5
Condon 175 Hha I GCGC 37 ccgcgccatggc gcgctcatggtgg 75 60 31
catct ggg
Exon 6
Condon 213 Taq I TCGA 65 gtccccaggcct taacccctcctccc 188 65 34
ctgattcctc agagaccccag
Exon 7
Condon 248 Msp I CCGG 37 ttggctctgactgt agtgtgcagggtg 137 60 31
Condon 249 Hae III GGCC 37 accac gcaag
Exon 8
Condon 282 Msp I CCGG 37 cctcttgcttctcttt cttggtctcctccac 262 60 31
tcctatcc cgcttcttg
PCR control Mutated sample
Undigested PCR band
DNA ladder
Digested PCR bands
Figure 1 Example of an RSM experiment involving the Msp I restriction
enzyme of codon 248 and DNA extracted from nine Barrett’s tissues. The
right-hand lane contains a positive control for the PCR step and shows the
expected PCR band size. The left-hand lane contains a DNA ladder
showing the 100, 200 and 300bp bands. The central lanes contain DNA
from Barrett’s biopsies subject to RSM analysis. The highlighted lane
contains an undigested band of the correct size and was subject to DNA
sequencing where it was confirmed that it contained a GC to AT mutation.
The remaining lanes (including the internal digestion control situated next
to the PCR-positive control) have digested and hence do not contain
mutations in this restriction site (codon 248).
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s(CEQ2000 Beckman Coulter). Both strands were sequenced
and only mutations apparent on both strands were accepted.
In the case of the exon 5 mutated sequences, the PCR product
(75bp) was too small to be sequenced directly and was firstly
cloned using the TA cloning method (Invitrogen NV Leek, The
Netherlands).
RESULTS
Detection of p53 mutations in Barrett’s tissues
No p53 mutations were detectable in any of the biopsies taken
from the four patients with squamous epithelium, nor were any
undigested products obtained with the internal digestion control.
This suggests that mutation artefacts were not introduced during
the methodology and that all mutations subsequently detected
were genuinely present in the Barrett’s tissues. Table 3 contains the
details of the p53 mutations detected in Barrett’s tissues. In total,
13 of the 38 patients with Barrett’s oesophagus (36%) were shown
to contain p53 mutations in at least one of their biopsies. Two
patients (patients 13 and 38) possessed different p53 mutations in
different biopsies, and seven out of 13 patients containing
mutations were shown to contain a p53 mutation in more than
one biopsy (with patient 4 having seven identical p53 mutations
recovered from the eight biopsies available). The fact that
seven out of eight different biopsies of patient 4 produced an
identical p53 mutation may be considered a validation of the
reproducibility of this approach in detecting p53 mutations in
Barrett’s tissues.
Correlation of p53 mutation with histology
Of the 13 patients who were histologically classed as having
metaplasia, four patients possessed a p53 mutation in at least one
biopsy. In the case of LGD, four out of 14 patients possessed a p53
mutation. Of the 11 patients with HGD, a further five contained
p53 mutations in a least one biopsy (see Figure 2). There was no
statistically significant difference in the number of p53 mutations
in squamous tissue vs metaplastic tissue (P¼0.4), or low-grade
dysplastic tissue (P¼0.33) or high-grade dysplastic tissue
(P¼0.15). The reported incidence of p53 gene mutation in
adenocarcinomas is in the range 50 – 88% (Table 1), which
corresponds well with the trend shown in Figure 2. However, it
should be pointed out that we used a method here with a
reasonably high sensitivity, whereas the previously published data
were obtained with low-sensitivity methods, and hence compar-
isons may be difficult.
Seven of the 13 patients with p53 mutations were shown to
contain multiple mutated tissue samples. As an indication of the
clonal expansion of p53 mutated cells, six of these were dysplastic
patients (three LGD, three HGD), suggesting that this clonal
expansion step was linked to the histological progression of
Barrett’s tissues (P¼0.13).
Table 3 p53 mutations detected in this study; details of the histology of the patients bearing p53 mutations
are included, along with details of the mutation itself (base change, amino-acid change)
Patient
number
Histological
stage
Mutations
per biopsy
Mutated
p53 condon
p53
mutation
Amino-acid
change
2 HGD 1/2 1 at 248 cgg-cag Arg-Gln
3 HGD 2/4 2 at 248 cgg-cag Arg-Gln
4 HGD 7/8 7 at 248 cgg-cag Arg-Gln
6 BM 2/5 2 at 248 cgg-cag Arg-Gln
8 HGD 2/5 2 at 248 cgg-cag Arg-Gln
12 BM 1/2 1 at 175 cgc-cac Arg-His
13 LGD 2/6 1 at 175 cgc-tgc Arg-Gln
1 at 248 cgg-cag Arg-Cys
18 BM 1/1 1 at 248 cgg-cag Arg-Gln
26 LGD 2/2 2 at 282 cgg-cgt No change
31 LGD 1/2 1 at 248 cgg-cag Arg-Gln
33 BM 1/2 1 at 248 cgg-tgg Arg-Trp
38 LGD 3/2 2 at 248 cgg-cag Arg-Gln
1 at 175 cgc-cac Arg-His
42 HGD 1/1 1 at 248 cgg-tgg Arg-Trp
Squamous
Metaplasia
LGD
HGD
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Figure 2 Role of p53 mutation in Barrett’s progression. The proportion
of patients with p53 mutations are correlated with histological grade. This
figure shows the accumulation of p53 mutation with histological grade.
From Table 1 it can be seen that 50 – 88% of adenocarcinomas have been
shown to contain p53 mutations. Hence fitting well with the trend
observed in this figure, however, the differing sensitivities of the methods
used make true comparison difficult.
p53 mutations in Barrett’s tissue
GJS Jenkins et al
1274
British Journal of Cancer (2003) 88(8), 1271–1276 & 2003 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sp53 mutation types detected in Barrett’s tissues
A total of 26 mutational events were detectable in the 465 RSM
experiments performed. These mutations were mostly recovered
from codon 248 (Msp I restriction site), with 21 of the mutations
(80%) being found here, three mutations (12%) were recovered
from codon 175 (Hha I restriction site), with the final two
mutations (8%) at codon 282 (Msp I restriction site). The fact that
the majority of p53 mutations were located at codon 248 suggests
that this codon is particularly targeted in Barrett’s progression.
This is supported by the fact that codon 248 is the most common
mutation hotspot in all human tumours (p53 mutation database:
www.IARC.fr/p53/) and that Barrett’s tumour p53 mutations, in
particular, are often located at codon 248 (Table 1). No mutations
were recovered from codons 213 (Taq I restriction site) or 249
(Hae III restriction site), despite reports of frequent polymorph-
isms in Barrett’s patients at codon 213 (Hamelin et al, 1994;
Campomenosi et al, 1996). Of the 26 mutations recovered, nearly
all (92%) were GC to AT transitions at CpG sites, supporting
previous data with regard to p53 mutations in Barrett’s tumours
(Gleeson et al, 1995, 1998).
DISCUSSION
Importantly, this study shows that a subset of tissues from
nondysplastic Barrett’s patients contain p53 mutations that may
predispose those patients to tumour development. Previous
reports have established that p53 mutation data can be used as a
predictive marker for cancer development in Barrett’s patients
(Schneider et al, 1996), and that the presence of p53 mutations can
predict poor 5-year survival rates of Barrett’s tumour patients
postoperatively (Schneider et al, 2000). p53 mutation has also been
shown to be useful as a predictive marker for the occurrence of
metastases in Barrett’s tumour patients (Casson et al, 1991; Bian
et al, 2001). Finally, p53 mutation data have also been used to
predict the poor response of Barrett’s tumour patients to
photodynamic therapy (Krishnadath et al, 2000). p53 mutation
therefore shows promise as a biomarker in Barrett’s patients
(Gleeson et al, 1998; Reid, 2001), but its use as an early biomarker
for risk of cancer development relies on its detection as early as
possible in premalignant Barrett’s tissues.
We have shown here that the application of a molecular
technique, that is, RSM, has allowed the detection of low-frequency
p53 mutations in premalignant Barrett’s tissues. As has been
pointed out previously, it is not feasible to use direct DNA
sequencing as a clinical tool to detect p53 mutation in Barrett’s
patients (Reid, 2001). However, the RSM method appears to be well
suited in scanning the hotspot codons of p53 for early mutations,
which would be undetectable by less-sensitive contemporary
techniques. We show that the appearance of p53 mutated cells
can occur at the metaplasia stage, with the clonal expansion of
these mutated cells occurring at the dysplastic stage.
It is interesting to note that two of the patients were shown to
have different p53 mutations in different biopsies, thus indicating
that divergent clonal evolution may be occurring in their Barrett’s
segments. It has previously been suggested that early neoplasia
may well have a multifocal nature leading to oligoclonal
development (Jankowski et al, 1999). These lines of evidence
point to the Barrett’s epithelium being the subject of high levels of
genetic evolution as a result of continuous exposure to potent
mutagenic agents, for example, ROS. Most of the p53 mutations
detected were present at CpG sites. CpG sites are known to be
susceptible to spontaneous deamination of methylated cytosine,
leading to the conversion of C to T (Pfeiffer, 2000). This process is
thought to be enhanced by exposure to ROS (Ambs et al, 1999),
possibly implicating inflammation-induced ROS in the develop-
ment of tumours in Barrett’s patients.
There are indeed notable similarities in the mutation profile
(types and positions) detected here in Barrett’s patients and those
p53 mutations previously shown by ourselves to be induced by the
model ROS hydrogen peroxide in vitro (Jenkins et al, 2001a,b).
This adds weight to the argument that ROS produced during
inflammation may play a role in cancer development in Barrett’s
tissues and may be responsible for the p53 mutations detected
here.
The potential value of p53 as a biomarker depends upon
whether it can be shown that possession of a p53 mutation either
affects the risk of cancer progression in Barrett’s patients, or
affects the rate at which this sequence unfolds. Only long-term
follow-up of these patients will answer this question. The fact that
p53 mutation abundance appears to increase during histological
progression suggests that this abnormality plays an important
driving role in carcinogenesis in Barrett’s tissues.
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